Scholar Rock stock weighs FDA approval against a USD 109.9 million loss

Scholar Rock stock stood at USD 49.85 on Nasdaq on September 23, 2026, down 2.62 percent for the session and 19.3 percent below its 52-week high of USD 61.76. The company is now balancing an FDA-approved therapy against a quarterly net loss of USD 109.9 million.

FDA approval changes the story

Scholar Rock received U.S. approval for ISEMBYLD, also known as apitegromab-mstn, on September 11, 2026. The treatment is approved for adults and children at least 2 years old with spinal muscular atrophy who already receive an SMN2-targeted therapy, according to StockTitan.

The approval is supported by the Phase 3 SAPPHIRE trial. Patients receiving ISEMBYLD plus an SMN2-targeted treatment showed a 2.2-point improvement on the HFMSE motor-function scale compared with treatment alone after one year, the filing said.

Losses remain substantial

Scholar Rock reported a Q2 2026 net loss of USD 109.9 million, or negative USD 0.84 per share, with no revenue for the quarter, according to StockTitan. The finance charge compares with a Q1 2026 net loss of USD 105.5 million and negative USD 0.83 diluted EPS.

Cash and cash equivalents stood at USD 437.1 million on June 30, 2026, while operating cash flow was negative USD 70.3 million in Q2. That balance gives the launch effort financial capacity, but the absence of quarterly revenue keeps commercial execution central to the valuation.

Analysts raise their targets

JPMorgan raised its Scholar Rock price target from USD 63 to USD 70 on September 22, 2026, while maintaining an overweight rating, according to MarketBeat. The target revision contrasts with the stock's 19.3 percent gap below its yearly high and places greater emphasis on the commercial rollout of ISEMBYLD.

Stock remains below its yearly high

Scholar Rock stock was quoted at USD 49.85 on Nasdaq on September 23, 2026, with a market capitalization of USD 5,973,425,800. The 52-week range was USD 27.07 to USD 61.76, making the FDA approval and the first launch metrics the next measurable tests for the shares.